Friday, 17 Aug 2018

You are here

15% of Users Exceed Recommended OTC NSAID Dosing

New data shows that nearly 15 percent of adult ibuprofen users exceed the maximum recommended dose of ibuprofen or other NSAIDs in a one-week period. 

An online study analyzed NSAID use with a 1-week diary study that included 1326 ibuprofen users. The vast majority (90%) of ibuprofen use was from over-the-counter use.

One third (37%) took non-ibuprofen NSAIDs adn the rest, ibuprofen. Those that exceeded the recommended daily NSAID limits included 11% on ibuprofen and 4% on other NSAIDs. This occurred an average of 9.1% of NSAID usage days.

Those with excessive daily use were more likely to  be male, with ongoing pain, poor physical function, daily smoking, and the attitude of “choosing my own dose” and not starting with the lowest dose.  They also had poor knowledge of the recommended 1-time and 24-hour dose limits.

Educating consumers about OTC NSAIDs use and their dosing directions could reduce excessive dosing and potential toxicity.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.